AstraZeneca’s Amolyt takeout among largest ever for a French biotech

AstraZeneca’s acquisition of Amolyt for $800 million up front will give the pharma a late-stage endocrinology asset for its Alexion portfolio while providing a return to investors who poured nearly $300 million into the start-up, mostly in the past five years.

With the purchase of Amolyt Pharma S.A.S., AstraZeneca plc (LSE:AZN; NASDAQ:AZN) will obtain PTH1R agonist eneboparatide, which entered Phase III testing for hypoparathyroidism last year. Results on the study’s primary endpoint are due in November 2024, according to ClinicalTrials.gov...